Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0164 | 0.5 | 0.5 |
Mycobacterium ulcerans | 3-alpha-hydroxysteroid dehydrogenase | 0.0164 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0164 | 0.5 | 0.5 | |
Leishmania major | oxidoreductase-like protein | 0.0164 | 0.5 | 0.5 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0164 | 0.5 | 0.5 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0164 | 0.5 | 0.5 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0164 | 0.5 | 0.5 |
Toxoplasma gondii | 2,4-dienoyl CoA reductase 2, peroxisomal family protein | 0.0164 | 0.5 | 0.5 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0164 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0164 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.